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Toscana virus (TOSV) is an emerging pathogen in the Mediterranean basin where it causes summertime
outbreaks of aseptic meningitis and meningoencephalitis. Many aspects of TOSV biology remain
unknown including the possible implication of an amplifying mammalian host besides its vector. The
three experiments described here were designed to assess the relationship between TOSV and type-I
interferon (IFN) response. The main ﬁndings were as follows. First, TOSV growth in Vero cells is sensitive
to an antiviral state induced by low-dose addition of exogenous IFN beta (IFN-β) (10 IU/ml). Second, no
IFN-βmRNA or IFN-βwas detectable after infection of HeLa and 293T cells by TOSV. Finally, TOSV inhibits
IFN-β production induced by Sendaï virus, a well known inducer of IFN-β production. In addition to
showing that TOSV can inhibit the IFN-β response, these ﬁndings suggest that anti-IFN capability is
maintained by regular contact with that of a mammalian host.
& 2013 Elsevier Inc. All rights reserved.Introduction
One of the main early defense mechanisms of the innate
mammalian immune system involves production and secretion
of interferon beta (IFN-β) during various pathogenic processes
including viral infection. This cellular response triggers expression
of IFN-stimulated genes (ISGs) that encode proteins able to inhibit
virus multiplication and spread (Haller et al., 2006; Versteeg and
Garcia-Sastre, 2010). However, many viruses have developed anti-
IFN strategies (Haller et al., 2006; Randall and Goodbourn, 2008).
The study described here focuses on the relationship between
Toscana virus (TOSV) and the type-I interferon (IFN) response.
TOSV is an arthropod-borne virus (family Bunyaviridae, genus
Phlebovirus) transmitted to humans by sandﬂies (Verani et al., 1984).
It is of medical importance around the Mediterranean basin where it
causes outbreaks of acute meningitis and meningoencephalitis in
local populations as well as returning tourists mainly during sum-
mertime when the vector population reaches its maximum density
(Brisbarre et al., 2011; Cusi et al., 2010; Kay et al., 2010). A 7-year
study performed in Siena, Italy, showed that TOSV was implicated in
52% of aseptic meningitis-meningoencephalitis of suspected viral
origin (Giorgi et al., 1991).ll rights reserved.
ité de Virologie, Antenne de
n, France.
onet).TOSV is an enveloped virus with a single-stranded RNA genome
composed of 3 segments. The large (L) segment is of negative
polarity and codes for the RNA-dependent RNA-polymerase
(Accardi et al., 1993). The medium (M) segment is also of negative
polarity and codes for 2 glycoproteins (GN and GC) and a non-
structural protein (NSM) (Di Bonito et al., 1997; Gro et al., 1997).
The small (S) segment has an ambisense coding strategy and
contains the nucleoprotein (N) gene in negative orientation and
the non-structural protein gene in positive orientation (Giorgi
et al., 1991).
Several viruses in the Bunyaviridae family including La Crosse
virus, Bunyamwera virus, and Rift Valley fever virus have devel-
oped anti-IFN strategies implicating NSS proteins (Elliott and
Weber, 2009; Hollidge et al., 2011). In this regard, it has been
reported that TOSV can replicate in BHK21 cells that exhibit a
type-I IFN response as well as in Vero cells that do not exhibit a
type-I IFN response (Charrel et al., 2005). Interestingly, recent data
suggests that TOSV triggers production of IFN-β but is not sensitive
to the type-I IFN response since it possesses a canonical phlebo-
virus NSS protein capable of inhibiting IFN-β production (Gori
Savellini et al., 2011).
The purpose of this report is to describe three sets of experi-
ments designed to assess the relationship between IFN response
and TOSV isolates from the two currently identiﬁed lineages, i.e.,
Italian (lineage A) and Spanish (lineage B) (Collao et al., 2009). Our
ﬁndings indicated that both lineages were sensitive to the antiviral
state induced by IFN-β and that the virus inhibits this antiviral
response, likely by means of a NSS protein (Elliott and Weber,
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innate immune defenses, our ﬁndings support the hypothesis of a
mammalian host for TOSV.Results
Effect of IFN-β treatment on TOSV replication
The ﬁrst set of experiments was designed to assess the
sensitivity of TOSV to increasing doses of exogenous IFN-β. Two
batches of Vero cells, which do not secrete type-I IFN but can be
stimulated by exogenous IFN (Desmyter et al., 1968), were pre-
treated overnight with exogenous IFN-β and infected with TOSV
(isolate either from Italian or Spanish lineage) or vesicular stoma-
titis virus (VSV), a known IFN-sensitive virus (Meager, 2002). After
removal of the inoculum, fresh medium containing exogenous IFN-
β was added. Virus titers were determined in supernatants at 24,
48, and 72 hours post infection (h.p.i.).
Results showed that the Italian TOSV isolate used was sensitive
to IFN-β treatment at all concentrations (Fig. 1A and B). Using the
lowest IFN-β concentration (10 IU/ml), virus titers at 24 h.p.i. were
2 to 3 orders of magnitude lower than the untreated control (0 IU/
ml). Although the response of the two batches of Vero cells was
globally similar, differences in sensitivity to IFN-β treatment and
TOSV infection were noted. It was in expectation of this behavior
that we decided to use two batches from the same cell line but
with different origins and/or passage histories and possibly pre-
senting different phenotypes. In the 1st batch of Vero cells, the
effects of IFN-β treatment on viral titer were only transient and the
difference between the treated (10, 100 and 1000 IU/ml) and
untreated (0 IU/ml) cells diminished with time to reach only
1 order of magnitude by 72 h.p.i. (Fig. 1A). In the 2nd batch,
exogenous IFN-β treatment almost completely inhibited TOSV
growth at all assay times (Fig. 1B) in all wells except the one
treated with the lowest concentration (10 IU/ml) in which the
virus grew slightly from 6.102 PFU/ml at 24 h.p.i. to 4.103 PFU/ml at
72 h.p.i. Control experiments using VSV conﬁrmed that exogenous
treatment induced an antiviral state in both batches. As in test
experiments with TOSV, growth of VSV was less affected in the 1st
than 2nd batch. In the 1st batch, virus titers decreased by twoFig. 1. Effect of IFN-β on TOSV andorders of magnitude at a IFN-β concentration of 10 IU/ml and
4 logs at 1000 IU/ml (Fig. 1C). In the 2nd batch, the drop in virus
titer was 6 orders of magnitude at 10 IU/ml and 7 logs at 1000 IU/
ml (Fig. 1D).
To demonstrate that these results were not speciﬁc to a single
TOSV lineage or isolate, i.e. the Italian lineage, a second series of
experiments were carried out using a second TOSV isolate related
to the Spanish lineage (Fig. 1E) (Peyreﬁtte et al., 2005). Results
with the Spanish isolate were similar to those with the Italian
isolate. Strong inhibition of viral growth was observed even at the
lowest IFN-β concentration that induced a growth reduction
greater than 4 orders of magnitude at 72 h.p.i. (Fig. 1E). Taken
together, the results of the ﬁrst and second series of experiments
demonstrated that TOSV is susceptible to the antiviral state
induced by exogenous IFN-β in Vero cells and that this response
cannot be attributed to either Vero cell batch or TOSV isolate.
Absence of IFN-β production after TOSV infection
A second set of experiments was carried out to determine if
TOSV could trigger IFN-β production in 293T and HeLa cells.
Cultured cells were infected at a MOI of 3 with either TOSV or
Sendaï virus (SeV), a known inducer of type-I IFN production. Both
TOSV (Fig. 2A) and SeV (Fig. 2B) grew/replicated. However, while
SeV replication triggered production of IFN-β as previously
reported (Strahle et al., 2006), TOSV elicited no detectable amount
of IFN-β (Fig. 2C and D).
To conﬁrm this observation, a more sensitive method, i.e., RT-
qPCR, was used to detect IFN-β mRNA levels. Again, production of
IFN-βmRNAwas detected in 293T and HeLa cells infected with SeV
(Fig. 2E and F). After TOSV infection, 293T cells produced no IFN-β
mRNA (Fig. 2E) but HeLa cells showed a small increase in mRNA
levels (Fig. 2F).
To further investigate potential production of type-I IFN in HeLa
cells, a four-step bioassay was performed on Vero cells as follows:
overnight treatment with either supernatants from the previous
experiment or known amounts of exogenous IFN-β, infection with
VSV, collection of cell supernatant at 24 h.p.i., and determination
of VSV titers (Fig. 2G and H). Using known amounts of exogenous
IFN-β, a clear drop (1 log) in VSV titers was observed starting at
5 IU/ml and becoming undetectable at 100 IU/ml (data notVSV replication in Vero cells.
Fig. 2. IFN-β production by 293T or HeLa cells infected either with TOSV or SeV.
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cells, a strong anti-VSV effect was observed in complete accor-
dance with the high levels of IFN-β previously detected by theELISA assay (always more than 200 IU/ml, Fig. 2C and D). When
this bioassay was performed on TOSV-infected 293T and HeLa cell
supernatants, no type-I IFN-related response was observed, thus
Fig. 3. Inhibition of IFN-β production by TOSV.
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produce IFN-β after infection with SeV was severely or completely
inhibited by TOSV infection.Inhibitory effect of TOSV on IFN-β
Demonstration of the absence of IFN-β production after TOSV
infection raised two hypotheses, i.e., ability of the virus is to elude
cell sensors (toll-like receptors or RIG-I-like receptors) or produc-
tion by the virus of at least one viral protein able to stop the type-I
IFN response before or during IFN-β production. Based on a
previous report implicating TOSV NSs in inhibition of IFN-β
production (Gori Savellini et al., 2011), we decided to focus on
the second hypothesis. Accordingly another set of experiments
involving sequential co-infection of 293T cells ﬁrst with TOSV and
thenwith SeV was carried out to determine if TOSV inhibited IFN-β
production induced by SeV. Results showed that, while SeV alone
triggers IFN-β production, neither TOSV-infected cells nor sequen-
tially infected cells (TOSV followed by SeV) produced any detect-
able level of IFN-β (Fig. 3A). To rule out the possibility that
sequential infection affects the ability of either virus to replicate,
we performed titration of cell supernatants to check for TOSV
production of infectious particles (Fig. 3B) and extracted cellular
RNA to measure SeV replication (Fig. 3C). In cells co-infected with
SeV, TOSV titers increased throughout the experiment indicating
that TOSV did grow in the presence of SeV although titers were
lower than in cells infected with TOSV alone (Fig. 3B). Similarly,
active, albeit reduced, replication of SeV was observed in sequen-
tially infected cells (Fig. 3C). The reduction in RNA replication and
protein production by both TOSV and SeV likely resulted from
competition for intracellular resources.
Taken together, the results of these experiments clearly
demonstrated that TOSV prevented IFN-β production induced bySeV in 293T cells. It thus seems safe to assume TOSV actively
inhibits IFN-β production.Discussion
The three sets of experiments described here demonstrate the
ability of TOSV isolates from two different lineages to inhibit the
IFN-β production in two different cell lines. The ﬁrst set showed
that TOSV isolates from both different lineages were susceptible to
the antiviral state induced by addition of exogenous IFN-β to Vero
cell cultures. Findings in the second set showed that infection with
TOSV did not trigger the type-I IFN response in IFN-β competent
cells. Finally, the third set conﬁrmed the preceding results by
showing that TOSV inhibited the IFN-β production induced by SeV.
The ﬁndings of this study have signiﬁcant bearing on a long-
standing debate regarding the natural life cycle of TOSV, i.e., the
existence of a viral reservoir. Although vertical transmission of the
virus among phlebotomine vectors is possible, Tesh and Modi
(1987) reported that, the percentage of transovarially infected ﬂies
declined from 86% to 5.8% from F5 to F12 generations. This
suggests that TOSV cannot be maintained in P. perniciosus by
transovarial transmission alone and that alternative mechanisms
of ampliﬁcation must exist in nature. In this regard, laboratory
studies by Tesh et al. (1992) demonstrated sexual transmission of a
phlebovirus in sandﬂies. Two other alternatives could be venereal
transmission or the existence of a mammalian host in the replica-
tion cycle of TOSV. However, animal sampling, albeit limited,
in the Mediterranean basin where the virus is of medical sig-
niﬁcance has detected it only once in a bat and serological traces of
TOSV infection have never been conﬁrmed in any animal (Navarro-
Mari et al., 2011; Verani et al., 1988). The possibility that humans
serve as an ampliﬁcation host seems unlikely since viremia is
short-lived and low during human infection, thus reducing the
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infected human.
The main implication of our experiments in human cells (293T
and HeLa cells) is that TOSV has an active anti-IFN system against
the mammalian IFN defense mechanism. Since sandﬂies, like other
insects, do not have an IFN system (Merkling and van Rij, 2013), it
can be surmised that maintenance of the functionality of this anti-
IFN system requires regular contact with another host possessing
an IFN system. Furthermore, since the IFN system is species-
speciﬁc with few cross reactions (Schultz et al., 2004), it also
seems safe to assume that the second host is mammalian. Con-
ﬁrmation of this hypothesis and identiﬁcation of this host would
represent a signiﬁcant advance in the understanding of the natural
life cycle of the virus and potentially better protection of human
populations.
Our experimental data also shed new light on the previously
published results of Gori Savellini and collaborators (Gori Savellini
et al., 2011) who reported that an Italian isolate of TOSV possessed
an anti-IFN NSs but its expression occurred too late in the virus
cycle to be signiﬁcant. Thus, unlike the isolates used in this study,
the isolate used by Gori Savellini triggered the production of IFN-β.
Despite this apparent discrepancy, the results of the two studies
were similar with regard to two points. First, Gori Savellini's based
their conclusion that the isolate was not sensitive to IFN-β
treatment on the fact that viral titers observed at 24 h.p.i. in the
TOSV-infected cell supernatants were the same with as without
1000 IU/ml of IFN-β. In fact, though the Italian and Spanish isolates
behaved differently, the values observed at 24 h.p.i. in our study
were quite similar. This difference could be due to the measure-
ment technique which consisted of monitoring titer kinetics in our
study as opposed to single-point determination in Gori Savellini's
study. A second point on which our results and those of Gori
Savellini are in agreement involved inhibition of IFN-β production
by TOSV NSs in Gori Savellini's results and by TOSV in our ﬁndings.
Our results are in agreement with this ﬁnding. It is thus possible
that the difference between the two studies stems simply from the
use of isolates with different characteristics, namely regarding the
timing of anti-IFN NSs protein production timing, i.e., early versus
late. Further experiments will be needed to address this issue and
eventually correlate it with differences in pathogenesis.
Two batches of Vero cells from different laboratories, batch 1
(A, C) and batch 2 (B, D, E), were pretreated overnight with 0, 10,
100 or 1000 IU human IFN-β/ml. Cells were infected at a MOI of
0.1 with a clinical TOSV isolate (It¼ Italian lineage) (A, B) or the
TOSV H/IMTSSA isolate (Sp¼Spanish lineage) (E) or VSV (C, D). At
24, 48 and 72 hours post infection (h.p.i.), supernatants were
collected and virus titers were assayed. Error bars represent the
standard deviation between independent triplicates (A–B) or
duplicates (C–D).
HeLa or 293T cells were infected with TOSV or SeV at MOI of 3.
At indicated times, supernatants and cells were harvested and
total RNA was extracted after cell lysis. The following determina-
tions were made (A) TOSV titers in supernatants, (B) intracellular
SeV equivalent number of genome copies by RT-qPCR, (C, D)
amount of extracellular IFN-β using a human IFN-β ELISA kit, and
(E, F), intracellular increase of IFN-β mRNA by RT-qPCR. Finally, a
bioassay (G, H) was performed to conﬁrm the ELISA results.
Following overnight incubation with the harvested supernatants,
the supernatants were removed, Vero cells were washed and
infected with VSV. After 24 h, VSV titers in the supernatants were
determined. Error bars represent standard deviations between at
least two independent experiments. The horizontal bar indicates
the detection limit of the assay.
293T cells were sequentially infected with TOSV and SeV with
an interval of 5 h. Both infections were carried out at a MOI of 3. At
0, 16, 24 and 48 hour post infection (h.p.i.), cell supernatants werecollected and IFN-β concentration (ELISA assay) (A) or TOSV titers
(B) was determined. At indicated times, cells were collected and
total RNA was extracted. SeV equivalent number of genome copies
was determined by RT-qPCR (C). Error bars represent standard
deviations between two independent experiments.Material and methods
Cells and virus
293T, HeLa and two different batches of Vero cells were grown
in monolayers in Dulbecco's modiﬁed Eagle medium (DMEM, high
glucose, GlutaMAX™, pyruvate, Invitrogen) complemented with
10% heat-inactivated fetal calf serum (FCS) (Lonza) at 37 1C in
5% CO2.
Two TOSV isolates were used, i.e., a French isolate of Spanish
lineage, H/IMTSSA (AY766034), and an isolate related to Italian
lineage from a clinical sample displaying a sequence similar to
Pubmed acc. # X53794. Dr Dacheux (Lyssavirus Dynamics and
Host Adaptation Unit, Pasteur, France) and Dr Roux (Department of
Microbiology and Molecular Medicine, University of Geneva,
Faculty of Medicine, Switzerland) kindly provided VSV and SeV
respectively. Stocks of VSV and TOSV were obtained by infecting
Vero cells at a MOI of 0.1 for 24 and 96 hour post infection (h.p.i.)
respectively. All cell lines were checked for mycoplasma contam-
ination using the MycoProbe Mycoplasma Detection Kit (R&D
systems).
Virus titration
Titration of TOSV was performed by plaque assay. Brieﬂy,
tenfold dilutions were used to infect 90% conﬂuent Vero cells for
1 h at 37 1C in DMEM (2% FCS) in a 6-well plate. Inoculum was
then removed and replaced by an overlay medium containing 0.5%
puriﬁed agar (LONZA) and 1X Eagle's minimal essential medium
(EMEM) complemented with 7% FCS and 1% L-Glutamine. At 96 h.
p.i., cells were ﬁxed with formaldehyde and, after removal of the
overlay medium, stained with crystal violet.
VSV titers were determined by end-point dilution assay. Brieﬂy,
tenfold dilutions were used to infect conﬂuent Vero cells in a 96-
wells plate in DMEM (2% FCS) at 37 1C. Wells were classiﬁed as
positive (cythopatic effect) versus negative (no cytopathic effect)
24 h.p.i. and TCID50/ml was determined using the Reed–Muench
method.
IFN-β sensitivity assay
To investigate the sensitivity of TOSV to IFN-β, Vero cells were
seeded in a 24-well plate at 2105 cells/well. To ensure results
were not batch-dependent, two cell batches were used, i.e., one
from our lab and another kindly provided by JC de la Torre (TSRI,
California). Cells were pretreated overnight with exogenous
human IFN-β (0, 10, 100, and 1000 IU/ml) (PBL interferon source,
human interferon beta 1b). The ﬁnal volume in the well was 1 ml.
Cells were then infected with TOSV (2 isolates) and VSV in
DMEM (2% FCS) at a MOI of 0.1. After incubation for 1 h, the
inoculum was removed, cells were washed with PBS, and fresh
DMEM (5% FCS) containing 0, 10, 100, and 1000 IU/ml of IFN-β was
added. Supernatants were collected at 24, 48 and 72 h.p.i. and viral
titers were determined.
Induction and quantiﬁcation of IFN-β
Experiments to determine the capability of TOSV to induce IFN-
β production were carried out on 293T and HeLa cells. The day
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well). Cells were infected with TOSV and SeV at a MOI of 3 in
DMEM (2% FCS). After incubation for 1 h, the inoculum was
removed, cells were washed with PBS, and fresh DMEM (5% FCS)
was added.
For the co-infection assay, 293T or HeLa cells were infected
with TOSV at a MOI of 3 during an interval of 5 h. The inoculum
was then removed, cells were washed with PBS and then infected
with SeV at a MOI of 3. After incubation for 1 h, inoculum was
removed and fresh medium was added.
At indicated times after infection, IFN-β levels in cell super-
natants were determined using a human IFN-β ELISA kit (PBL
Interferon Source).
RT-qPCR
At indicated times, cells were collected in RLT buffer, homo-
genized with QIAshreder columns and total RNA was extracted
using the RNeasy Mini Kit (QIAgen), following manufacturer's
recommendations. SeV equivalent number of genome copies and
mRNA IFN-β were determined by RT-qPCR using a primer/probe
system. The following primers and probes were used:
IFN-β mRNA
5′-AAACTCATGAGCAGTCTGCA-3′ (Fwd); 5′-AGGAGATCTTCAGT-
TTCGGAGG-3′ (Rev); 5′-ATGGTCCAGGCACAGTGACTGTCCTC-3′
(Probe) (Jaworska et al., 2007). SeV: 5′-GCAATAACGGTGTCGAT-
CACG-3′ (Fwd); 5′-TGCCTGAGCCGATCGG-3′ (Rev); 5′-CGAAGAT-
GAC0GATACCGCAGCAGTAGC-3′ (Probe) (Strahle et al., 2006).
Normalization of RT-qPCR data was obtained using the 18S house-
keeping gene (Applied Biosystems).
RT-qPCR was performed using the Superscript III Platinum One
Step Quantitative RT-PCR System (Invitrogen). 5 ml of total RNA
was added to 15 ml of RT-qPCR mix containing 2 reaction mix
buffer, enzyme mix, 1 mM of each primer, and 0.8 mM of Taqman
probe. Ampliﬁcation was performed in a LightCycler II Instrument
(Roche Diagnostics). Fluorescence reading was performed after
cycling as follows: RT at 45 1C for 15 min followed by 40 cycles for
15 sec 95 1C (ramp rate, 20 1C/s), 5 sec 57 1C (ramp rate, 20 1C/s),
and 30 sec 60 1C (ramp rate, 20 1C/s).
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